Mercy BioAnalytics

Mercy BioAnalytics

  • Founded: 2018
  • Location: Natick, MA
  • Employee range: 11 - 50
  • Funding: $41M A Apr 2023
  • Investors: Novalis LifeSciences, Sozo Ventures, Hatteras Venture Partners, iSelect Fund, American Cancer Society BrightEdge, Broadway Angels, Labcorp, Bruker


mercybio.com

linkedin.com

job board


Short description:

Early cancer detection based on analysis of single extracellular vesicles 

Drug notes:

Contact us to add description: recruit@workinbiotech.com

Long description:

Mercy BioAnalytics is on a mission to improve cancer detection through early diagnosis when it is most curable. Mercy BioAnalytics utilizes a liquid biopsy platform, the Mercy Halo™ test, which analyzes extracellular vesicles in the blood. Liquid biopsies are minimally invasive compared to traditional tissue biopsies, and early detection allows for more effective treatment options and improved patient outcomes. A specific type of extracellular vesicle called exosomes, are shed by cancer cells and express specific surface markers that could be used as cancer biomarkers for this highly needed early detection method. Mercy is initially focusing on difficult-to-treat cancers like ovarian and lung cancer. The co-founders also created the Mercy Foundation to help underserved populations.

Jobs:


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com